Vertex director plans $663K stock sale

VERTEX PHARMACEUTICALS INC / MA (VRTX) has a notice of proposed sale filed for shares of its common stock under Rule 144.

Rhea-AI Filing Summary

VERTEX PHARMACEUTICALS INC / MA (VRTX) has a notice of proposed sale filed for shares of its common stock under Rule 144. Director Bruce I. Sachs plans to sell 1,210 shares of Vertex common stock through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $662,535.50. The shares were acquired as a gift and are held jointly with Kimberlie T. Sachs as JTWROS. As of this notice, 253,460,924 shares of Vertex common stock were outstanding, and the shares are listed on NASDAQ. The remark states that shares are sold through the Watercove Charitable Foundation, where Bruce I. Sachs serves as trustee.

Key Figures

Number of shares to be sold: 1,210 shares Aggregate market value: $662,535.50 Shares outstanding: 253,460,924 shares +1 more

4 metrics

Number of shares to be sold 1,210 shares Common stock covered by the Rule 144 notice

Aggregate market value $662,535.50 Market value of the 1,210 shares proposed to be sold

Shares outstanding 253,460,924 shares Vertex common stock outstanding in connection with this notice

Date of Notice 08/27/2026 Date the Form 144 notice was signed and filed

Key Terms

Rule 144, aggregate market value, JTWROS, charitable foundation

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"Common | Goldman Sachs & Co. LLC ... | 1210 | 662535.5 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

JTWROS financial

"Bruce I. Sachs & Kimberlie T. Sachs JTWROS | | 02/15/2008 |"

charitable foundation financial

"Shares sold through the Watercove Charitable Foundation where Bruce I."

A charitable foundation is a non-profit organization established to collect and manage funds to support charitable activities, such as education, health, or community projects. It acts like a financial reservoir dedicated to giving back to society, often funded by individuals, families, or corporations. For investors, supporting or donating to such foundations can enhance social impact and may offer tax benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for VRTX?

The Form 144 discloses that Bruce I. Sachs, a director, plans to sell 1,210 shares of Vertex Pharmaceuticals common stock under Rule 144 through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $662,535.50 and 253,460,924 shares outstanding.

How many VRTX shares are proposed to be sold and at what value?

The notice covers a proposed sale of 1,210 shares of Vertex Pharmaceuticals common stock, with an indicated aggregate market value of $662,535.50 at the time of the filing.

Who is selling Vertex (VRTX) shares under this Form 144 and through which broker?

The proposed sale is for the account of Bruce I. Sachs, a director of Vertex, with the transaction to be executed through Goldman Sachs & Co. LLC as the broker.

How were the Vertex (VRTX) shares being sold under Form 144 originally acquired?

The 1,210 shares of Vertex common stock covered by this notice were acquired as a gift and are held by Bruce I. Sachs & Kimberlie T. Sachs JTWROS (joint tenants with right of survivorship).

What does the Form 144 say about Vertex (VRTX) shares outstanding?

The filing states that there were 253,460,924 shares of Vertex Pharmaceuticals common stock outstanding in connection with this proposed Rule 144 sale.

What charitable detail is mentioned in this Vertex (VRTX) Form 144?

A remark states that the shares are sold through the Watercove Charitable Foundation, where Bruce I. Sachs serves as trustee.

On which exchange are the Vertex (VRTX) shares in this Form 144 listed?

The common stock covered by this Form 144 notice is listed on NASDAQ, as stated in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:47 PM EDT Accepted by SEC EDGAR 08/27/2026 - 04:46 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001197036
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vertex Pharmaceuticals Incorporated
SEC File Number	000-19319
Address of Issuer	50 Northern Avenue Boston MASSACHUSETTS 02210
Phone	1-617-341-6100
Name of Person for Whose Account the Securities are To Be Sold	Bruce I. Sachs
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	1210	662535.5	253460924	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/13/2023	Acquired as a gift	Bruce I. Sachs & Kimberlie T. Sachs JTWROS		02/15/2008	1210	04/13/2023	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold through the Watercove Charitable Foundation where Bruce I. Sachs serves as trustee.
Date of Notice	08/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Bruce I. Sachs
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)